Citations

Mayo Clinic

Showing 10 of 108523 citations.

Proton Pencil Beam Scanning Facilitates the Safe Treatment of Extended Radiation Targets for Hodgkin Lymphoma: A Report from the Proton Collaborative Group Registry
Ebadi, Maryam , Pankuch, Mark , Boyer, Sean, Chang, J. , Stevens, Craig , Hall, Matthew D. , Bates, James E. , Flampouri, Stella , Kole, Adam J. , Mohindra, Pranshu , Rossi, Carl J., Sanghvi, Parag, McGee, L.A. , Rana, Zaker , Tseng, Yolanda D. , Kole, Adam J , Mohindra, Pranshu , McGee, Lisa, Tseng, Yolanda D , Hall, Matthew D , Hasan, Shaakir

Cancers | August 1, 2024 | Volume: 16 | Issue: 15 | Pages: 2736

10.3390/cancers16152736 | PMID 39123464 Get It

Because proton beam therapy (PBT) can lower the dose of radiation to the heart, lungs, and breast, it is an established radiation modality for patients with Hodgkin lymphoma (HL). Pencil beam scanning (PBS) PBT facilitates the treatment of more extensive targets. This may be especially of value for lymphoma patients who require RT to both mediastinal and axillary targets, defined here as extended target RT (ETRT), given the target distribution and need to minimize the lung, heart, and breast dose. Using the Proton Collaborative Group registry, we identified patients with HL treated with PBT to both their mediastinum and axilla, for which DICOM-RT was available. All patients were treated with PBS. To evaluate the dosimetric impact of PBS, we compared delivered PBS plans with VMAT butterfly photon plans optimized to have the same target volume coverage, when feasible. Between 2016 and 2021, twelve patients (median 26 years) received PBS ETRT (median 30.6 Gy (RBE)). Despite the large superior/inferior (SI, median 22.2 cm) and left/right (LR, median 22.8 cm) extent of the ETRT targets, all patients were treated with one isocenter except for two patients (both with SI and LR > 30 cm). Most commonly, anterior beams, with or without posterior beams, were used. Compared to photons, PBS had greater target coverage, better conformity, and lower dose heterogeneity while achieving lower doses to the lungs and heart, but not to the breast. No acute grade 3+ toxicities were reported, including pneumonitis. Proton ETRT in this small cohort was safely delivered with PBS and was associated with an improved sparing of the heart and lungs compared to VMAT.
Molecular Pathways and Potential Therapeutic Targets of Refractory Asthma
Ishmael, Leah , Casale, Thomas B. , Cardet, Juan Carlos , Casale, Thomas

Biology | August 1, 2024 | Volume: 13 | Issue: 8 | Pages: 583

10.3390/biology13080583 | PMID 39194521 Get It

Asthma is a chronic inflammatory lung disease. Refractory asthma poses a significant challenge in management due to its resistance to standard therapies. Key molecular pathways of refractory asthma include T2 inflammation mediated by Th2 and ILC2 cells, eosinophils, and cytokines including IL-4, IL-5, and IL-13. Additionally, non-T2 mechanisms involving neutrophils, macrophages, IL-1, IL-6, and IL-17 mediate a corticosteroid resistant phenotype. Mediators including alarmins (IL-25, IL-33, TSLP) and OX40L have overlap between T2 and non-T2 inflammation and may signify unique pathways of asthma inflammation. Therapies that target these pathways and mediators have proven to be effective in reducing exacerbations and improving lung function in subsets of severe asthma patients. However, there are patients with severe asthma who do not respond to approved therapies. Small molecule inhibitors, such as JAK-inhibitors, and monoclonal antibodies targeting mast cells, IL-1, IL-6, IL-33, TNFα, and OX40L are under investigation for their potential to modulate inflammation involved in refractory asthma. Understanding refractory asthma heterogeneity and identifying mediators involved are essential in developing therapeutic interventions for patients unresponsive to currently approved biologics. Further investigation is needed to develop personalized treatments based on these molecular insights to potentially offer more effective treatments for this complex disease.
Cardiovascular Toxicities of Immune Therapies for Cancer – A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology
Tocchetti, Carlo G. , Farmakis, Dimitrios , Koop, Yvonne , Andrés, María Sol , Formisano, Luigi , Ciardiello, Fortunato, Emmerich, Max , Plummer, Chris , Gulati, Geeta , Ramalingam, Sivatharshini , Brezden‐Masley, Christine , Iakobishvili, Zaza , Bergler‐Klein, Jutta , Boer, Rudolf A. de , Rassaf, Tienush, Fradley, Michael G. , Moslehi, Javid J. , Yang, Eric H., Neilan, Tomas G. , Herrmann, Joerg , Mirabel, Mariana , Skouri, Hadi , Cohen‐Solal, Alain , Sverdlov, Aaron L. , Meer, Peter van der, Asteggiano, Riccardo , Ky, Bonnie , Seferović, Petar , Metra, Marco , Rosano, Giuseppe, Suter, Thomas, Tocchetti, Carlo Gabriele , López-Fernández, Teresa , de Boer, Rudolf A , Ky, Bonnie , Sverdlov, Aaron L , Metra, Marco , Couch, Liam Steven , Ciardiello, Fortunato , Pane, Fabrizio , Au, Lewis , Cardinale, Daniela , Thavendiranathan, Paaladinesh , Santoro, Ciro , Keramida, Kalliopi , Maack, Christoph , Lutgens, Esther , Rassaf, Tienush , Yang, Eric H., Keulenaer, Gilles W. De , Ameri, Pietro , Bax, Jeroen J. , Mbakwem, Amam , Hirsch, Emilio , Meer, Peter van der , Barac, Ana , Lenihan, Daniel , Dent, Susan , Coats, Andrew J.S. , López‐Fernández, Teresa , Lyon, Alexander R.

European Journal of Heart Failure | August 1, 2024 | Volume: 26 | Issue: 10 | Pages: 2055-2076

10.1002/ejhf.3340 | PMID 39087551 Get It

ABSTRACT The advent of immunological therapies has revolutionized the treatment of solid and haematological cancers over the last decade. Licensed therapies which activate the immune system to target cancer cells can be broadly divided into two classes. The first class are antibodies that inhibit immune checkpoint signalling, known as immune checkpoint inhibitors (ICIs). The second class are cell-based immune therapies including chimeric antigen receptor T lymphocyte (CAR-T) cell therapies, natural killer (NK) cell therapies, and tumour infiltrating lymphocyte (TIL) therapies. The clinical efficacy of all these treatments generally outweighs the risks, but there is a high rate of immune-related adverse events (irAEs), which are often unpredictable in timing with clinical sequalae ranging from mild (e.g. rash) to severe or even fatal (e.g. myocarditis, cytokine release syndrome) and reversible to permanent (e.g. endocrinopathies).The mechanisms underpinning irAE pathology vary across different irAE complications and syndromes, reflecting the broad clinical phenotypes observed and the variability of different individual immune responses, and are poorly understood overall. Immune-related cardiovascular toxicities have emerged, and our understanding has evolved from focussing initially on rare but fatal ICI-related myocarditis with cardiogenic shock to more common complications including less severe ICI-related myocarditis, pericarditis, arrhythmias, including conduction system disease and heart block, non-inflammatory heart failure, takotsubo syndrome and coronary artery disease. In this scientific statement on the cardiovascular toxicities of immune therapies for cancer, we summarize the pathophysiology, epidemiology, diagnosis, and management of ICI, CAR-T, NK, and TIL therapies. We also highlight gaps in the literature and where future research should focus.
Editorial. Two novel models to optimize transitional care in spina bifida: the patient as provider and the congenital neurosurgeon in active collaboration
Bevans, Shannon, Swana, Hubert S., Pattisapu, Jogi V. , Hopson, Betsy , Harmon, Daniel, Blount, Jeffrey P. , Foy, Andrew , Clarke, Michelle J.

Neurosurgical Focus | August 1, 2024 | Volume: 57 | Issue: 2 | Pages: E2

10.3171/2024.6.focus24387 | PMID 39088857 Get It

Predictors of Delayed Clinical Benefit Following Surgical Treatment for Low-grade Spondylolisthesis
Djurasovic, Mladen, Bisson, Erica F. , Chan, Andrew K. , Bydon, Mohamad , Mummaneni, Praveen V., Foley, Kevin T. , Shaffrey, Christopher I. , Potts, Eric A. , Shaffrey, Mark E., Coric, Domagoj , Knightly, John J. , Wang, Michael Y. , Fu, Kai-Ming, Slotkin, Jonathan R., Virk, Michael S., Chou, Dean , Haid, Regis W., Glassman, Steven D. , Carreon, Leah Y. , Mummaneni, Praveen V. , Park, Paul , Fu, Kai-Ming, Asher, Anthony L., Virk, Michael S.

Spine | August 1, 2024 | Volume: 50 | Issue: 11 | Pages: E213-E218

10.1097/brs.0000000000005115 | PMID 39087454 Get It

Study Design. Retrospective review of prospectively collected data. Objective. The aim of this study was to investigate what factors predict delayed improvement after surgical treatment of low-grade spondylolisthesis. Summary of Background Data. Lumbar surgery leads to clinical improvement in the majority of patients with low-grade spondylolisthesis. Most patients improve rapidly after surgery, but some patients demonstrate a delayed clinical course. Methods. The Quality and Outcomes Database (QOD) was queried for grade 1 spondylolisthesis patients who underwent surgery who had patient-reported outcome measures (PROMs) collected at baseline, 3, 6, and 12 months, including back and leg pain Numeric Rating Scale (NRS), Oswestry Disability Index (ODI), and EuroQol-5D (EQ-5D). Patients were stratified as “early responders” reaching MCID at 3 months and maintaining improvement through 12 months and “delayed responders” not reaching MCID at 3 months but ultimately reaching MCID at 12 months. These two groups were compared with respect to factors which predicted delayed improvement. Results. Of 608 patients enrolled, 436 (72%) met inclusion criteria for this study. Overall, 317 patients (72.7%) reached MCID for ODI at 12 months following surgery. Of these patients, 249 (78.5%) exhibited a rapid clinical improvement trajectory and had achieved ODI MCID threshold by the 3-month postoperative follow-up. Sixty-eight patients (21.4%) showed a delayed trajectory, and had not achieved ODI MCID threshold at 3 months, but did ultimately reach MCID at 12-month follow-up. Factors associated with delayed improvement included impaired preoperative ambulatory status, better baseline back and leg pain scores, and worse 3-month leg pain scores ( P <0.01). Conclusions. The majority of patients undergoing surgery for low-grade spondylolisthesis reach ODI MCID threshold rapidly, within the first 3 months after surgery. Factors associated with a delayed clinical course include impaired preoperative ambulation status, relatively better preoperative back and leg pain, and persistent leg pain at 3 months.
Epidemiologic changes in thyroid disease
Acosta, Gonzalo J. , Ospina, Naykky Singh , Brito, Juan P. , Ospina, Naykky Singh , Singh Ospina, Naykky , Brito, Juan P

Current Opinion in Endocrinology, Diabetes & Obesity | August 1, 2024 | Volume: 31 | Issue: 5 | Pages: 184-190

10.1097/med.0000000000000877 | PMID 39087407 Get It

Purpose of review To analyze the evolving epidemiologic trends in thyroid disease, focusing on risk factors, underlying drivers of these changes, and their implications on clinical practice and research priorities. Recent findings Thyroid disease remains one of the most prevalent groups of disorders globally, and the shift in its frequency and distribution is multifactorial. The prevalence of hypothyroidism increases with age, although normal thyrotropin ranges appear to be age-dependent, raising concern for potentially inappropriate levothyroxine use. Hyperthyroidism and Graves’ disease continue to be predominant in reproductive-age women but exhibit a milder phenotype at diagnosis. Thyroid nodules are increasingly found in asymptomatic patients, likely from more widespread use of neck and chest imaging. Thyroid cancer incidence has risen exponentially over the years, mostly driven by overdiagnosis of low-risk tumors; however, a small rise in incidence of higher risk tumors has been noted. Obesity appears to be a risk factor for thyroid cancer occurrence and more aggressive forms of the disease. Summary Understanding epidemiologic trends in thyroid disease is crucial for guiding clinical practice and research efforts, aiming to optimize patient outcomes while preventing unnecessary and potentially harmful interventions.
Long‐term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow‐up in the SELECTION open‐label long‐term extension study
Feagan, Brian G., Matsuoka, Katsuyoshi , Rogler, Gerhard , Laharie, David , Vermeire, Séverine , Loftus, Edward V. , Beales, Ian , Schreiber, Stefan , Kim, Hyo Jong , Faes, Margaux , Haas, Angela de, Masior, Tomasz , Rudolph, Christine , Danese, Silvio , Loftus, Edward V , Beales, Ian , Schreiber, Stefan , Peyrin-Biroulet, Laurent , Vermeire, Séverine , Danese, Silvio , Peyrin‐Biroulet, Laurent , Matsuoka, K

Alimentary Pharmacology & Therapeutics | August 1, 2024 | Volume: 60 | Issue: 5 | Pages: 563-584

10.1111/apt.18158 | PMID 39086130 Get It

SummaryBackgroundFilgotinib, an oral, once‐daily, Janus kinase 1 preferential inhibitor, is an approved treatment for moderately to severely active ulcerative colitis.AimsThe aim of this study is to assess the safety and efficacy of continued filgotinib therapy over ~4 years in the long‐term extension of the phase 2b/3 SELECTION trial (SELECTIONLTE; NCT02914535).MethodsIn this interim analysis of SELECTIONLTE, SELECTION completers (week 10 responders to filgotinib who completed the maintenance study) continued their assigned treatment (double‐blind filgotinib 200 mg [FIL200] or filgotinib 100 mg) and SELECTION week 10 non‐responders received open‐label FIL200. We assessed safety by adverse events (AEs), and efficacy by partial Mayo Clinic Score (pMCS), inflammatory biomarkers and health‐related quality of life (HRQoL). We compared safety and efficacy between achievers and non‐achievers of a multi‐component endpoint, comprehensive disease control (CDC), comprising symptomatic, endoscopic, inflammatory biomarker and HRQoL improvements.ResultsData for completers (n = 250) and non‐responders (n = 372) were reported for ≤202 weeks. AE occurrences were low and consistent with previous analyses. The as‐observed proportion of FIL200‐treated patients in pMCS, biomarker and HRQoL remission during SELECTIONLTE remained high among completers (week 144: 80.0%, 86.4% and 86.0%, respectively) and increased among non‐responders (week 192: 62.1%, 76.7% and 59.3%, respectively). Significantly higher proportions of CDC achievers at SELECTION week 58 achieved pMCS, IBDQ and corticosteroid‐free pMCS remission than non‐achievers, up to LTE week 96.ConclusionsFilgotinib induced and maintained symptomatic remission and improved HRQoL over 4 years. Safety results showed a proven long‐term benefit–risk profile. FIL200‐treated CDC achievers had better long‐term outcomes than non‐achievers.
A Proposed Framework for the Advancement of National Quality Improvement Collaborative Efforts
Reilly, Eileen, Janczewski, Lauren M. , Nelson, Heidi , Joung, Rachel Hae‐Soo

Annals of Surgery | August 1, 2024 | Volume: 281 | Issue: 1 | Pages: 80-82

10.1097/sla.0000000000006467 | PMID 39087320 Get It

Intracranial Atherosclerotic Disease and Incident Dementia: The ARIC Study (Atherosclerosis Risk in Communities)
Zhao, Di , Güallar, Eliseo , Qiao, Ye , Knopman, David S. , Palatino, Maylin, Mosley, Thomas H. , Wasserman, Bruce A. , Mosley, Thomas H. , Knopman, David S. , Gottesman, Rebecca F , Wasserman, Bruce A , Guallar, Eliseo , Gottesman, Rebecca F.

Circulation | August 1, 2024 | Volume: 150 | Issue: 11 | Pages: 838-847

10.1161/circulationaha.123.067003 | PMID 39087353 Get It

BACKGROUND: Studies of the neurovascular contribution to dementia have largely focused on cerebral small vessel disease (CSVD), but the role of intracranial atherosclerotic disease (ICAD) remains unknown in the general population. The objective of this study was to determine the risk of incident dementia from ICAD after adjusting for CSVD and cardiovascular risk factors in a US community-based cohort. METHODS: We acquired brain magnetic resonance imaging examinations from 2011 through 2013 in 1980 Black and White participants in the ARIC study (Atherosclerosis Risk in Communities), a prospective cohort conducted in 4 US communities. Magnetic resonance imaging examinations included high-resolution vessel wall magnetic resonance imaging and magnetic resonance angiography to identify ICAD. Of these participants, 1590 without dementia, without missing covariates, and with adequate magnetic resonance image quality were followed through 2019 for incident dementia. Associations between ICAD and incident dementia were assessed using Cox proportional hazard ratios adjusted for CSVD (characterized by white matter hyperintensities, lacunar infarctions, and microhemorrhages), APOE4 genotype (apolipoprotein E gene ε4), and cardiovascular risk factors. RESULTS: The mean age (SD) of study participants was 77.4 (5.2) years. ICAD was detected in 34.6% of participants. After a median follow-up of 5.6 years, 286 participants developed dementia. Compared with participants without ICAD, the fully adjusted hazard ratios (95% CIs) for incident dementia in participants with any ICAD, with ICAD only causing stenosis ≤50%, and with ICAD causing stenosis >50% in ≥1 vessel were 1.57 (1.17–2.11), 1.41 (1.02–1.95), and 1.94 (1.32–2.84), respectively. ICAD was associated with dementia even among participants with low white matter hyperintensities burden, a marker of CSVD. CONCLUSIONS: ICAD was associated with an increased risk of incident dementia, independent of CSVD, APOE4 genotype, and cardiovascular risk factors. The increased risk of dementia was evident even among participants with low CSVD burden, a group less likely to be affected by vascular dementia, and in participants with ICAD causing only low-grade stenosis. Our results suggest that ICAD may partially mediate the effect that cardiovascular risk factors have on the brain leading to dementia. Both ICAD and CSVD must be considered to understand the vascular contributions to cognitive decline.
Management of pyoderma gangrenosum during pregnancy and breastfeeding: a systematic review
Wanberg, Lindsey J , Gorman, Benjamin G. , Theis‐Mahon, Nicole , Alavi, Afsáneh , Alavi, A , Goldfarb, Noah

International Journal of Dermatology | August 1, 2024 | Volume: 64 | Issue: 1 | Pages: 11-14

10.1111/ijd.17402 | PMID 39086027 Get It

AbstractPregnancy is a conjectured risk factor for pyoderma gangrenosum (PG), an autoinflammatory neutrophilic dermatosis characterized by painful ulcers. Even so, there are no available treatment guidelines for those with PG who are pregnant or breastfeeding. To describe existing treatment options, we systematically reviewed the literature on PG treatment in pregnant or breastfeeding patients. A search over four databases was completed in October 2022. Independent reviewers accomplished screening and data extraction. 18 articles met the inclusion criteria. 15 cases involved the treatment of PG during pregnancy, and three cases involved the treatment of PG while breastfeeding. Most patients did not have a history of PG prior to pregnancy (77.7%), and most did not have PG‐associated comorbidity (61.1%). Of the cases involving treatment of PG during pregnancy, the majority (73%) found treatment success with a systemic corticosteroid (SCS). Only three cases reported an adverse outcome, including premature rupture of membranes and premature birth (16.7%); all these cases involved treatment with a SCS at >0.5 mg/kg/day during pregnancy. We present a treatment algorithm for pregnant or breastfeeding patients with PG. Our findings suggest prioritizing topicals and TNF inhibitors due to more favorable side effect profiles. However, there is a paucity of data on the safety of PG therapies in pregnancy and breastfeeding, and thus, controlled studies and pregnancy registries must be pursued.